Keywords: six-month, epilog, data, reveal, sustained, benefits, previously-reported
Six-Month EPILOG Data Reveal Sustained Benefits
Article | 18 November 1996
The previously-reported benefits of treating angioplasty patients with Eli Lilly/Centocor's glycoprotein IIb/IIIa antagonist ReoPro (abciximab or c7E3; ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
